ClinicalTrials.gg
RecruitingNCT04578301PERSEVEREUpdated May 18, 2022

Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease

An observational study in Liver Cirrhosis, Portal Hypertension and Surgery, sponsored by University Hospital, Bonn. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-18.

Sponsored by University Hospital, Bonn · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Liver Cirrhosis with a site in Germany — 24 open to participants now, 27 under way, 2 of them phase 3. Liver Cirrhosis · Germany.

Planned enrollment
19th of 37
200 · median 200
Started
2020
with 3 others
Observational
37 of 82
15 open now
Primary completion
2025-12
later than 9 of 26 live
Registered
43rd of 82
by date

Among the 82 studies in Liver Cirrhosis with a site in Germany, this one is the 19th largest by planned enrollment of the 37 observational ones that give a count, is one of 4 that started in 2020, is one of 37 observational ones, reaches primary completion later than 9 of the 26 other live ones, and was the 43rd registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

24 of the 82 studies in Liver Cirrhosis with a site in Germany are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Liver Cirrhosis with a site in Germany, or all of them as a file.
02

Study summary

Prospective, observational study to define precipitants and predictors of development of Acute-on-Chronic Liver Failure (ACLF) after surgical interventions, allowing to develop a risk stratification for elective procedures in cirrhotic patients. As well as identifying molecular mechanisms of post-interventional ACLF and thus preparing the ground for development of new therapeutic approaches.

Read the detailed description

Background: Acute-on-chronic liver failure (ACLF) is a recently discovered syndrome, which is understood as an acute deterioration of decompen-sated liver cirrhosis. It is defined on the basis of organ failure(s) and associated with high short-term mortality. ACLF is caused by a precipi-tating event that results in excessive systemic inflammation. ACLF is mostly precipitated and associated with bacterial infections but 40-50% of the underlying cause is unclear. Surgery, with or without liver involvement, has been defined as such a precipitating event. It is long known, that surgery in liver cirrhotic patients, depending on stage of cirrhosis as well as on type of surgery, bears a great risk but is still in-evitable in some cases. Child-Turquotte Score has been used for risk stratification of postoperative mortality. The development and out-come of ACLF after surgical interventions have not been characterized yet. In addition, underlying causes as well as molecular mechanism leading to ACLF after surgical intervention have not been identified. The aim of this trial is to further prospectively investigate patients with cirrhosis undergoing surgery to identify clinical markers and molecular mechanisms involved in development of ACLF.

Objectives: Defining precipitants and predictors of development of ACLF after surgical interventions, allowing to develop a risk stratification for elective procedures in cirrhotic patients.

Identifying molecular mechanisms of post-interventional ACLF and thus preparing the ground for development of new therapeutic approaches.

Study design: Prospective, observational study. Patients will be screened according inclusion/exclusion criteria. After informed consent sample processing will be possible from max. 1 week before scheduled surgery.

Primary endpoints: Development of ACLF within 28 and 90 days after visceral or non-visceral surgery in patients with portal hypertension (liver cirrhosis and idiopathic non-cirrhotic portal hypertension)

Secondary endpoints:

  1. Mortality at 1 month, 3 months and 1 year.

    Following endpoints will be evaluated:

    " Time to death and mortality (overall and surgery-related) " Time to and rate of unplanned rehospitalizations after surgery " Any Infection and differentiated by site of infection (SBP, pneumonia, urinary tract infection, blood stream infection, Clostridium difficile-associated enterocolitis " Postsurgical acute hepatic decompensation and ACLF

  2. To assess the changes in the intestinal microbiota in both groups and evaluate its effect on the primary endpoint.
  3. To assess the potential socioeconomic impact.
03

Conditions studied

  • Liver Cirrhosis
  • Portal Hypertension
  • Surgery
  • Acute-On-Chronic Liver Failure
  • Non-Cirrhotic Portal Hypertension

Keywords

  • ACLF
  • Acute-On-Chronic Liver Failure
  • Liver Cirrhosis
  • Portal Hypertension
  • Surgery
  • Non-Cirrhotic Portal Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with and without liver cirrhosis and/or portal hypertension undergoing elective or emergency surgical intervention.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adult (≥18 years) patient
  • With or without liver cirrhosis (diagnosed either histologically or by a combination of clinical, laboratory and radiological signs)
  • Or Non-cirrhotic portal hypertension
  • Non-pregnant, non-lactating females
  • Ability to understand the patient information and to personally sign and date the to participate in the study
  • The patient is co-operative and available for the entire study
  • Provided written informed consent
  • Indication for surgical intervention

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Patients undergoing surgery as form of palliative cancer therapy
  • Presence or history of severe extra-hepatic diseases
  • -positive patients
  • Previous liver or other transplantation
  • Patients with acute or subacute liver failure without underlying cirrhosis
  • Patients who decline to participate
  • Physician´s denial (e.g. the investigator considers that the patient will not follow the protocol scheduled)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Surgery

    Patients with and without liver cirrhosis undergoing surgery.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    No Intervention

06

What researchers measure

Primary outcomes

  1. Episodes of Acute-on-Chronic Liver Failure (ACLF)

    Development of ACLF after surgery

    Time frame: 90 days

Secondary outcomes

  1. 1-year mortality

    Death after surgery

    Time frame: 12 months

  2. Episodes of Acute Decompensation

    Acute hepatic Decompensation after Surgery

    Time frame: 12 months

Other outcomes

  1. Intestinal Microbiota

    Intestinal Microbiota will be assessed in stool samples.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Dec 2025, 63 months after the start.

Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 63 months is above that.

Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2020
First posted
Oct 8, 2020
StartActual
Sep 22, 2020
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
May 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04578301
Responsible party
Michael Praktiknjo (PI, University Hospital, Bonn) — Principal investigator
First posted
Oct 8, 2020
Start date
Sep 22, 2020
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 18, 2022

Study contacts

Michael Praktiknjo, MD
Contact
michael.praktiknjo@ukbonn.de
+4922828716375
Johannes Chang, MD
Contact
johannes.chang@ukbonn.de
Michael Praktiknjo, MD
principal investigator · University Hospital, Bonn

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion